{"id":4426294,"date":"2026-03-09T07:40:00","date_gmt":"2026-03-09T12:40:00","guid":{"rendered":"https:\/\/olartemoure.com\/?p=4426294"},"modified":"2026-03-09T07:40:26","modified_gmt":"2026-03-09T12:40:26","slug":"fda-telehealth-practices","status":"publish","type":"post","link":"https:\/\/olartemoure.com\/en\/fda-telehealth-practices\/","title":{"rendered":"FDA on GLP-1 compounders and telehealth advertising practices"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; theme_builder_area=&#8221;post_content&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221;][et_pb_row _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; theme_builder_area=&#8221;post_content&#8221; width=&#8221;100%&#8221; hover_enabled=&#8221;0&#8243; sticky_enabled=&#8221;0&#8243;][et_pb_column _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; type=&#8221;4_4&#8243; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; theme_builder_area=&#8221;post_content&#8221; hover_enabled=&#8221;0&#8243; sticky_enabled=&#8221;0&#8243;]The U.S. Food and Drug Administration (FDA) has intensified its enforcement actions against companies marketing compounded GLP-1 products, issuing warning letters to 30 telehealth firms for allegedly making false or misleading claims. The agency is particularly focused on advertisements implying equivalence with FDA-approved drugs such as Novo Nordisk\u2019s Wegovy, and on attempts to bypass the regulatory approval process through compounded formulations. This marks the second major wave of warning letters in six months, signaling a broader and more aggressive compliance push against unlawful promotion, misbranding, and the online sale of unapproved drug products. [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The agency is particularly focused on advertisements implying equivalence with FDA-approved drugs such as Novo Nordisk\u2019s Wegovy.<\/p>\n","protected":false},"author":5,"featured_media":4426295,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[58,122],"tags":[],"class_list":["post-4426294","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newsletter","category-compliance-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA on GLP-1 compounders and telehealth advertising practices - OlarteMoure | Intellectual Property<\/title>\n<meta name=\"description\" content=\"The agency is particularly focused on advertisements implying equivalence with FDA-approved drugs such as Novo Nordisk\u2019s Wegovy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA on GLP-1 compounders and telehealth advertising practices\" \/>\n<meta property=\"og:description\" content=\"The agency is particularly focused on advertisements implying equivalence with FDA-approved drugs such as Novo Nordisk\u2019s Wegovy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/\" \/>\n<meta property=\"og:site_name\" content=\"OlarteMoure | Intellectual Property\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T12:40:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-09T12:40:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2026\/03\/telehealth.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1601\" \/>\n\t<meta property=\"og:image:height\" content=\"837\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nicole Diaz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicole Diaz\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/\"},\"author\":{\"name\":\"Nicole Diaz\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/39418ad779f2cd1c62156f11faaf2e31\"},\"headline\":\"FDA on GLP-1 compounders and telehealth advertising practices\",\"datePublished\":\"2026-03-09T12:40:00+00:00\",\"dateModified\":\"2026-03-09T12:40:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/\"},\"wordCount\":178,\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/telehealth.jpg\",\"articleSection\":[\"Newsletter\",\"Compliance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/\",\"name\":\"FDA on GLP-1 compounders and telehealth advertising practices - OlarteMoure | Intellectual Property\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/telehealth.jpg\",\"datePublished\":\"2026-03-09T12:40:00+00:00\",\"dateModified\":\"2026-03-09T12:40:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/39418ad779f2cd1c62156f11faaf2e31\"},\"description\":\"The agency is particularly focused on advertisements implying equivalence with FDA-approved drugs such as Novo Nordisk\u2019s Wegovy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/#primaryimage\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/telehealth.jpg\",\"contentUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/telehealth.jpg\",\"width\":1601,\"height\":837,\"caption\":\"telehealth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/fda-publicidad-telemedicina\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA on GLP-1 compounders and telehealth advertising practices\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/\",\"name\":\"OlarteMoure | Intellectual Property\",\"description\":\"Firma especializada en Propiedad Intelectual\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/olartemoure.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/39418ad779f2cd1c62156f11faaf2e31\",\"name\":\"Nicole Diaz\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g\",\"caption\":\"Nicole Diaz\"},\"sameAs\":[\"https:\\\/\\\/www.olartemoure.com\"],\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/author\\\/webmaster\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA on GLP-1 compounders and telehealth advertising practices - OlarteMoure | Intellectual Property","description":"The agency is particularly focused on advertisements implying equivalence with FDA-approved drugs such as Novo Nordisk\u2019s Wegovy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/","og_locale":"en_US","og_type":"article","og_title":"FDA on GLP-1 compounders and telehealth advertising practices","og_description":"The agency is particularly focused on advertisements implying equivalence with FDA-approved drugs such as Novo Nordisk\u2019s Wegovy.","og_url":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/","og_site_name":"OlarteMoure | Intellectual Property","article_published_time":"2026-03-09T12:40:00+00:00","article_modified_time":"2026-03-09T12:40:26+00:00","og_image":[{"width":1601,"height":837,"url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2026\/03\/telehealth.jpg","type":"image\/jpeg"}],"author":"Nicole Diaz","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicole Diaz","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/#article","isPartOf":{"@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/"},"author":{"name":"Nicole Diaz","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/39418ad779f2cd1c62156f11faaf2e31"},"headline":"FDA on GLP-1 compounders and telehealth advertising practices","datePublished":"2026-03-09T12:40:00+00:00","dateModified":"2026-03-09T12:40:26+00:00","mainEntityOfPage":{"@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/"},"wordCount":178,"image":{"@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2026\/03\/telehealth.jpg","articleSection":["Newsletter","Compliance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/","url":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/","name":"FDA on GLP-1 compounders and telehealth advertising practices - OlarteMoure | Intellectual Property","isPartOf":{"@id":"https:\/\/olartemoure.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/#primaryimage"},"image":{"@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2026\/03\/telehealth.jpg","datePublished":"2026-03-09T12:40:00+00:00","dateModified":"2026-03-09T12:40:26+00:00","author":{"@id":"https:\/\/olartemoure.com\/#\/schema\/person\/39418ad779f2cd1c62156f11faaf2e31"},"description":"The agency is particularly focused on advertisements implying equivalence with FDA-approved drugs such as Novo Nordisk\u2019s Wegovy.","breadcrumb":{"@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/#primaryimage","url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2026\/03\/telehealth.jpg","contentUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2026\/03\/telehealth.jpg","width":1601,"height":837,"caption":"telehealth"},{"@type":"BreadcrumbList","@id":"https:\/\/olartemoure.com\/fda-publicidad-telemedicina\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/olartemoure.com\/en\/"},{"@type":"ListItem","position":2,"name":"FDA on GLP-1 compounders and telehealth advertising practices"}]},{"@type":"WebSite","@id":"https:\/\/olartemoure.com\/#website","url":"https:\/\/olartemoure.com\/","name":"OlarteMoure | Intellectual Property","description":"Firma especializada en Propiedad Intelectual","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/olartemoure.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/39418ad779f2cd1c62156f11faaf2e31","name":"Nicole Diaz","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g","caption":"Nicole Diaz"},"sameAs":["https:\/\/www.olartemoure.com"],"url":"https:\/\/olartemoure.com\/en\/author\/webmaster\/"}]}},"_links":{"self":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/4426294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/comments?post=4426294"}],"version-history":[{"count":0,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/4426294\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media\/4426295"}],"wp:attachment":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media?parent=4426294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/categories?post=4426294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/tags?post=4426294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}